Hormone-Responsive Cancers: A Growing Health Concern
Latin America is experiencing a growing burden of hormone-responsive cancers, driven by demographic aging, urbanization, and changing lifestyle patterns. Breast cancer is the most frequently diagnosed malignancy among women across the region, with hormone receptor–positive (HR+) disease representing a substantial share of cases. Prostate cancer is a leading cancer among men, particularly in countries such as Brazil, Argentina, Mexico, and Chile, where increased life expectancy and improved diagnostic awareness are contributing to higher detection rates. These trends position hormone therapy as a central component of cancer care throughout Latin America.
In countries with more developed healthcare systems, such as Chile, Uruguay, and parts of Brazil, organized screening programs support earlier detection and prolonged use of adjuvant endocrine therapy. Elsewhere, delayed diagnosis remains common, resulting in higher reliance on systemic hormone therapy for advanced disease. Public health systems shoulder the majority of care, while private oncology centers in major cities provide access to more comprehensive endocrine treatment pathways.
In addition to breast and prostate cancer, other hormone-sensitive tumors, including select gynecologic cancers, contribute to endocrine therapy utilization. Gradual expansion of pathology and hormone receptor testing capacity is improving patient identification, although access remains uneven in rural and underserved areas.
Combination Regimens: A Growing Treatment Trend
Combination hormone therapy regimens are adopted in Latin American oncology practice, particularly for patients with advanced or high-risk disease. In HR+ breast cancer, endocrine agents such as aromatase inhibitors or selective estrogen receptor modulators are often combined with ovarian suppression or additional systemic therapies to enhance treatment effectiveness. Academic centers and specialized cancer institutes in Brazil, Argentina, and Mexico are leading the integration of these combination strategies into routine care.
Prostate cancer management across the region reflects growing use of combination approaches. Androgen deprivation therapy remains the treatment backbone, but it is paired with other hormonal agents or systemic therapies for metastatic or recurrent disease. While access varies between public and private sectors, regional clinical guidelines and physician training initiatives are supporting broader adoption of combination regimens aligned with international standards.
The expansion of combination hormone therapy is reinforced by regional collaboration, professional education, and the gradual harmonization of treatment protocols. Multidisciplinary tumor boards and cross-institutional networks are improving consistency of care, even amid healthcare system constraints. Combination hormone therapy is becoming a sophisticated element of cancer treatment across Latin America.
